Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NAC Attack in Retinitis Pigmentosa
NCT05537220Phase 3Active, not recruiting
- Sponsor
- Johns Hopkins University
- Start
- Oct 2023
- Primary completion
- May 2029
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 3 trial of acetylcysteine in retinitis pigmentosa (RP), sponsored by Johns Hopkins University. Started Oct 2023; status: active, not recruiting.
02
Drugs
acetylcysteine
03
Conditions
retinitis pigmentosa (RP)
Beyond the preview
Go deeper on NCT05537220.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05537220.